NextCODE has made a sharp exit. Just 15 months after some ex-deCode Genetics executives struck a deal with Amgen to create NextCODE, Chinese CRO WuXi PharmaTech has bought the genomic analysis startup for $65 million in cash.
Back last summer the U.K.'s Convergence Pharmaceuticals, a spinout from GlaxoSmithKline, was feeling bullish about its prospects after it wrapped up a positive mid-stage study of its lead drug for neuropathic pain. But rather than take the risky step of mounting an IPO--still a tough prospect in the U.K.--Convergence instead opted to sell to Biogen Idec, which is using the acquisition to beef up its pipeline in the field.
Shire has snapped up NPS Pharmaceuticals for $5.2 billion, in a deal aimed at beefing up its rare disease portfolio.
Shire has struck a deal to buy NPS Pharma and its rare disease drug portfolio for $46 a share, or $5.2 billion, making headlines for its go-it-alone strategy on the eve of the big JP Morgan conference in San Francisco.
AMRI, on the mend after a rough quarter, is laying out $60 million to expand its manufacturing footprint, agreeing to buy a couple of outposts from service provider Aptuit.
Chinese CRO giant WuXi PharmaTech is continuing its push into genomic sequencing, paying $65 million for NextCODE Health, a Big Data-focused spinout of the high-profile deCODE.
Last month, rumors swirled that serial buyer Valeant would be swearing off its modus operandi for a little while to focus on cutting down debt in the wake of its Allergan bid failure. But according to CEO J. Michael Pearson, those who expect Valeant to stray from its dealmaking ways have another thing coming.
Pharma M&A in 2014 hit a record-breaking $234 billion in announced acquisitions. Actavis led the pack with its $66 billion bid for Botox maker Allergan and $25 billion buyout of Forest Laboratories. But investors and analysts say 2015 could generate as many or more deals, with Pfizer, Valeant Pharmaceuticals, AbbVie and Shire expected to be in the mix.
Medtronic and Covidien are nearing the finish line of their pending $43 billion merger as Medtronic shareholders voted on Tuesday to approve the deal, following in the footsteps of a similar vote from Covidien shareholders.
Cardio3 BioSciences is buying the cancer division of Celdara Medical, trading $10 million up front and promising more in exchange for a seat at the immuno-oncology table.